Adalimumab vs. Conventional Immunosuppression for Corticosteroid-sparing for Uveitis (ADVISE) Trial

The ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial is a randomized, comparative effectiveness trial comparing adalimumab to conventional agent immunosuppression for patients with non-infectious, intermediate, posterior, and panuveitides. Scheie Eye Institute, the Department of Ophthalmology, University of Pennsylvania will not enroll any patients under 18 years of age.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  uveitis
• Age: - 99 Years
• Gender: All